Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$10.34 USD
-0.06 (-0.58%)
Updated May 6, 2024 04:00 PM ET
After-Market: $10.34 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FOLD 10.34 -0.06(-0.58%)
Will FOLD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FOLD
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
Other News for FOLD
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
Takeda said to have left industry trade group BIO
First Week of FOLD June 21st Options Trading
As more rare disease therapies launch, their prices are rising
WuXi Biologics Reports Solid 2023 Annual Results